Suppr超能文献

农村家庭医疗实践中的阿片类药物使用障碍药物辅助治疗。

Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.

机构信息

Mayo Clinic Health System-Northwest Wisconsin, Eau Claire, WI, USA.

University of Minnesota Medical School, Minneapolis, MN, USA.

出版信息

J Prim Care Community Health. 2020 Jan-Dec;11:2150132720931720. doi: 10.1177/2150132720931720.

Abstract

Opioid use disorder (OUD) is a cause of significant morbidity and mortality in the United States. Although efforts are being made to limit access to prescription opioids, the use of heroin and synthetic opioids as well as death due to opioid overdose has increased. Medication-assisted treatment (MAT) is the pairing of psychosocial intervention with a Food and Drug Administration (FDA)-approved medication (methadone, buprenorphine plus naltrexone) to treat OUD. MAT has resulted in reductions in overdose deaths, criminal activity, and infectious disease transmission. Access to MAT in rural areas is limited by shortages of addiction medicine-trained providers, lack of access to comprehensive addiction programs, transportation, and cost-related issues. Rural physicians express concern about lack of mentorship and drug diversion as reasons to avoid MAT. The prescribing of MAT with buprenorphine requires a Drug Enforcement Agency (DEA) waiver that can easily be obtained by Family Medicine providers. MAT can be incorporated into the outpatient practice, where patient follow-up rates and number needed to treat to effect change are similar to that of other chronic medical conditions. We describe a case of opioid overdose and a suggested protocol for the induction of MAT with buprenorphine/naloxone (Suboxone) for OUD in a rural family medicine outpatient practice. Treatment access is facilitated by utilizing the protocol, allowing office staff work to the extent allowed by their licensure, promoting teamwork and minimizing physician time commitment. We conclude that improved access to MAT can be accomplished in a rural family medicine outpatient clinic by staff that support and mentor one another through use of a MAT protocol.

摘要

阿片类药物使用障碍(OUD)是美国发病率和死亡率居高不下的主要原因之一。尽管目前正在努力限制处方阿片类药物的获取,但海洛因和合成阿片类药物的使用以及阿片类药物过量导致的死亡人数仍在增加。药物辅助治疗(MAT)是将心理社会干预与美国食品和药物管理局(FDA)批准的药物(美沙酮、丁丙诺啡加纳曲酮)相结合,用于治疗 OUD。MAT 已减少了过量死亡、犯罪活动和传染病的传播。农村地区获得 MAT 的机会受到成瘾医学培训提供者短缺、缺乏综合成瘾计划、交通和与成本相关问题的限制。农村医生表示,缺乏指导和药物滥用是他们避免 MAT 的原因。开处 MAT 中的丁丙诺啡需要药物管制局(DEA)的豁免,家庭医学医生很容易获得这种豁免。MAT 可以纳入门诊实践中,其患者随访率和需要治疗的人数与其他慢性疾病相似。我们描述了一个阿片类药物过量的病例,并提出了一个在农村家庭医学门诊实践中使用丁丙诺啡/纳洛酮(Suboxone)诱导 MAT 治疗 OUD 的建议方案。通过使用该方案,促进了治疗的获得,使办公室工作人员能够在其许可范围内开展工作,促进团队合作并最大限度地减少医生的时间投入。我们的结论是,通过使用 MAT 方案,支持和指导彼此的工作人员可以在农村家庭医学门诊诊所中改善 MAT 的可及性。

相似文献

4
Cost-effectiveness of Treatments for Opioid Use Disorder.阿片类药物使用障碍治疗的成本效益。
JAMA Psychiatry. 2021 Jul 1;78(7):767-777. doi: 10.1001/jamapsychiatry.2021.0247.
6
Medication Treatment of Opioid Use Disorder.阿片类药物使用障碍的药物治疗。
Biol Psychiatry. 2020 Jan 1;87(1):82-88. doi: 10.1016/j.biopsych.2019.06.020. Epub 2019 Jul 2.

本文引用的文献

2
Medication-Assisted Treatment for Opioid-Use Disorder.阿片类物质使用障碍的药物辅助治疗。
Mayo Clin Proc. 2019 Oct;94(10):2072-2086. doi: 10.1016/j.mayocp.2019.03.029. Epub 2019 Sep 19.
3
Fatalities caused by novel opioids: a review.新型阿片类药物所致死亡:综述
Forensic Sci Res. 2018 May 7;4(2):95-110. doi: 10.1080/20961790.2018.1460063. eCollection 2019.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验